Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation testing in metastatic colorectal cancer.

World journal of gastroenterology - 7 Oct 2012

Tan Cong, Du Xiang

Abstract excerpt

The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and KRAS mutational status testing has been highlighted in recent years. The most frequent mutations in this gene, point substitutions in codons 12 and 13, were validated as negative predictors of response to anti-epidermal growth factor receptor antibodies. Therefore, determining the KRAS mutational status of tumor samples has become an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Early Detection of Cancer
Share to Epidermal Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Genes, ras

Share to Neoplasm Metastasis

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 23066310
DOI: 10.3748/wjg.v18.i37.5171
PMCID: PMC3468848

Genes

KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation testing in metastatic colorectal cancer.PMID 23066310Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.Semantic proximity Read ↗

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

The current understanding on the impact of KRAS on colorectal cancer.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.